Good MorningThe S&P 500 pulled back on Thursday following better-than-expected results from Walmart. The world's largest retailer reported top and bottom-line outperformance driven by strength in all categories. The bad news is that guidance is weak and forecasts growth to slow. The result is a 6% decline in WMT's share price and market top that may remain in place until later this year.
Next week could be a volatile one for the S&P 500. The market faces earnings reports from numerous retailers and a critical economic release due Friday. The January read of the PCE price index is due and likely to confirm sticky inflation. The market could enter a correction in this scenario due to the impact on the FOMC rate reduction timeline. The FOMC is expected to lower interest rates, but the timing is uncertain and may not be until 2026. Featured: This tiny piece of glass could be bigger than GPUs (Ad) 
|
Consumer Staples | |
One of the most important things investors need to be aware of in the market is economic data, especially when the S&P 500 trades near or at its all-time highs, such as today. This is because the data will show investors what the charts won’t and that is whether the underlying economy ca... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Finance | |
Bridgewater Associates, founded by famed investor Ray Dalio, loaded up on shares of some big-name stocks in Q4. Bridgewater Associates recently released its Form 13F. Institutional investment managers with more than $100 million in discretionary control over 13F Securities must file this document.... Read the Full Story |
|
Consumer Staples | |
Walmart's (NYSE: WMT) February price correction is a buying signal for long-term investors. The drop is due to slowing growth and tariff fears but does little to alter the long-term outlook for earnings, cash flow, equity gains, and capital return. While slower growth and tariffs are headwinds f... Read the Full Story |
|
From Our Partners | | A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, right alongside SpaceX and Blue Origin.
It holds a special agreement to use a multi-billion dollar federal launch facility for just $500, and its customer list already includes the Pentagon, Lockheed Martin, and GE Aerospace.
Most Wall Street analysts have not caught on yet, but a major milestone could change that soon. | | Click here to see the company behind the gates |
|
Consumer Discretionary | |
Tesla Inc. (NASDAQ: TSLA) has had a wild ride over the past few months. In the weeks following Trump’s election victory, the stock soared 130%, reaching an all-time high in December before momentum stalled. Since then, shares have fallen more than 25%, with investors taking profits and shi... Read the Full Story |
|
Technology | |
High-profile stock market stories tend to carry a stigma for investors in the sense that few know whether it’s best to trade these names or just hold them for the long haul. Today, the largest share of attention and capital is centered around the technology sector in the United States, par... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Healthcare | |
Health insurance giant Humana Inc. (NYSE: HUM) stock initially rose in reaction to its fourth quarter of 2024 earnings report despite posting losses.
The medical sector giant was one of the first carriers to sound the alarm of rising inpatient utilization costs, notably with its Medicare Advant... Read the Full Story |
|
Technology | |
Three mega-cap names recently announced billions in share repurchase authorizations. Mega-cap generally refers to stock with market capitalizations of $200 billion or more. Below, I’ll detail exactly how large the buyback authorizations these huge firms have approved are. I’ll also inc... Read the Full Story |
|
Consumer Discretionary | |
However, retail and wholesale beauty stocks have been in a steady decline, with losses accelerating in 2025. Once a Wall Street favorite, Ulta Beauty Inc. (NASDAQ: ULTA) ended 2024 down 11.24% and is currently down 16.05% YTD. Coty Inc. (NYSE: COTY) fared worse, closing 2024 with a 43.96% loss and... Read the Full Story |
|
Consumer Discretionary | |
Most investors fall into what’s called “Indicator purgatory,” where they rely heavily on indicators and chart patterns to tell them where to start buying and selling in the market. However, there comes a point in the economic cycle, such as today, when those strategies become too... Read the Full Story |
|
Industrials | |
Fastenal Inc. (NASDAQ: FAST) is a leading supplier of construction and industrial supplies, including fasteners, bolts, screws, studs, washers, as well as safety supplies and tools for maintenance repair and operations (MRO) products. Muted industrial manufacturing and construction activity amid... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. | Should I Buy Merck & Co., Inc. Stock? MRK Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Merck & Co., Inc. was last updated on Thursday, August 27, 2026 at 6:04 PM.
Merck & Co., Inc. Bull Case -
Merck has demonstrated strong revenue growth, with a recent quarterly revenue increase of over 5% compared to the same period last year, indicating robust business performance.
-
The company has set an earnings per share (EPS) guidance for FY 2026 between 2.660 and 2.760, suggesting a positive outlook for profitability.
-
Merck's current stock price is around $147.60, which reflects a consensus rating of "Moderate Buy" from analysts, indicating potential for price appreciation.
-
The company recently announced a quarterly dividend of $0.85 per share, translating to an annualized dividend of $3.40, which provides a steady income stream for investors.
-
Merck's strong return on equity of 16.73% highlights its effective management and ability to generate profits from shareholders' equity, making it an attractive investment.
Merck & Co., Inc. Bear Case -
Merck's dividend payout ratio is currently at 272.00%, which is significantly high and may raise concerns about the sustainability of its dividend payments in the long term.
-
The company faces intense competition in the biopharmaceutical sector, particularly in oncology and vaccines, which could impact its market share and profitability.
-
Recent analyst ratings have shown mixed sentiments, with some firms maintaining a "neutral" rating, indicating uncertainty about future performance.
-
Merck's net margin of 4.77% is relatively low compared to industry standards, suggesting potential challenges in cost management and profitability.
-
Market volatility and economic uncertainties could adversely affect Merck's stock performance, making it a riskier investment in the current climate.
| | View Today's Stock Pick |
|
